Industry News
Research, Science & Manufacturer Updates
Biosimilars Articles
The U.S. Food and Drug Administration has approved Erelzi (etanercept-szzs), the first biosimilar etanercept, for all indications included in the reference product’s label.
The Centers for Medicare and Medicaid Services issued final rules detailing how it will pay for services provided to Medicare beneficiaries in 2016.
The Biosimilars Forum was launched by 11 of the leading biosimilar developers in the U.S.
The Centers for Medicare and Medicaid Services (CMS) plans to begin paying for biosimilars through its Part B,Part D and state coverage policies by this summer, according to a question-and-answer document released in April.
The U.S. Food and Drug Administration(FDA) has finalized three guidance documents outlining its expectations for biosimilars.
The Biosimilars 20/20 Conference, at two-day event that will provide an indepth look into the future of the biosimilars market and address challenges of implementation, is scheduled for June3 and 4 at The Hub in Philadelphia, Pa.